Related Experiment Video
Updated: Jun 5, 2026
05:12
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
Nanoparticles in Vascular Dementia: Advantages and Challenges
Xianxin Liu1,2, JiaLi Hu1,3,4, Yueming Qiu1,3,4
1Department of Pathology, Clinical Medical School of Jiujiang University, Jiujiang, Jiangxi, China.
CNS Neuroscience & Therapeutics
|June 4, 2026
Summary
Nanotechnology offers innovative diagnostic and therapeutic solutions for vascular dementia (VaD). Nanomaterials enable early detection and targeted treatment, addressing VaD
Area of Science:
- Integrative review of materials science, clinical medicine, and bioinformatics.
- Focus on nanomaterial applications in vascular dementia (VaD).
Background:
- Vascular dementia (VaD) is the second leading cause of dementia, stemming from cerebrovascular disorders.
- Current VaD treatments are limited to symptom management, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review the current status of nanomaterial research for VaD diagnosis and treatment.
- To analyze the therapeutic potential and challenges of nanomaterials in VaD.
Main Methods:
- Comprehensive literature review integrating materials science, clinical medicine, and bioinformatics.
- Analysis of molecular mechanisms and therapeutic applications of various nanomaterials in VaD.
Main Results:
- Nanomaterials aid in early diagnosis through high-contrast imaging of VaD biomarkers.
- Engineered nanocarriers target specific sites, penetrate the blood-brain barrier (BBB), and mitigate VaD pathology via angiogenesis, ROS scavenging, and neuroinflammation inhibition.
- Nanomaterials promote white matter repair and protect the neurovascular unit (NVU).
Conclusions:
- Nanotechnology presents a novel framework for intelligent, targeted diagnosis and treatment of VaD.
- Future research must address biocompatibility, long-term toxicity, and expand clinical trials for translation.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...